VEA
DNTH icon

Virtus ETF Advisers’s Dianthus Therapeutics DNTH Stock Holding History

Virtus ETF Advisers’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,025
Closed -$65.9K – 528
2024
Q4 		$65.9K Sell
3,025
-397
-12% -$10.2K 0.03% 413
2024
Q3 		$93.7K Buy
3,422
+64
+2% +$1.78K 0.04% 386
2024
Q2 		$86.9K Buy
+3,358
New +$80.7K 0.04% 375
2021
Q4 		– Sell
-1,169
Closed -$136K – 385
2021
Q3 		$136K Sell
1,169
-61
-5% -$7.11K 0.06% 356
2021
Q2 		$192K Buy
+1,230
New +$226K 0.08% 366
2019
Q4 		– Sell
-1,100
Closed -$181K – 469
2019
Q3 		$181K Sell
1,100
-61
-5% -$11.6K 0.04% 263
2019
Q2 		$274K Buy
+1,161
New +$287K 0.06% 257

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtus ETF Advisers's DNTH Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Dianthus Therapeutics (DNTH) in Q1 2025, closing a stake of 3,025 shares — an estimated $65.9K sold.

Virtus ETF Advisers first reported a position in DNTH in Q2 2019 and held it in 7 quarters. The position peaked at $274K in Q2 2019. 98 funds tracked by Wall St. Rank hold DNTH as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Dianthus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,025 Dianthus Therapeutics shares in Q1 2025, an estimated $65.9K.
  • Virtus ETF Advisers first reported a position in Dianthus Therapeutics in Q2 2019 and held it in 7 quarters.
  • Virtus ETF Advisers's Dianthus Therapeutics position peaked at $274K in Q2 2019.
  • 98 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.